

PATRICK DEVAL L

Form 4

July 10, 2018

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
PATRICK DEVAL L

(Last) (First) (Middle)

C/O GLOBAL BLOOD
THERAPEUTICS, INC., 171
OYSTER POINT BLVD, SUITE
300

(Street)

SOUTH SAN
FRANCISCO, CA 94080

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
Global Blood Therapeutics, Inc.
[GBT]

3. Date of Earliest Transaction
(Month/Day/Year)
07/06/2018

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)

☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	07/06/2018		M		15,000	A	\$ 28.45	15,000	D
Common Stock	07/06/2018		M		15,000	A	\$ 20	30,000	D
Common Stock	07/06/2018		M		8,361	A	\$ 20	38,361	D
Common Stock	07/06/2018		M		4,018	A	\$ 3.4	42,379	D

Edgar Filing: PATRICK DEVAL L - Form 4

Common Stock	07/06/2018	S	42,379	D	\$ 43.4008 (1)	0	D
-----------------	------------	---	--------	---	----------------------	---	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 28.45	07/06/2018		M	15,000	<u>(2)</u>	06/19/2027	Common Stock	15,000
Employee Stock Option (right to buy)	\$ 20	07/06/2018		M	15,000	<u>(3)</u>	08/10/2025	Common Stock	15,000
Employee Stock Option (right to buy)	\$ 20	07/06/2018		M	8,361	<u>(4)</u>	08/20/2025	Common Stock	8,361
Employee Stock Option (right to buy)	\$ 3.4	07/06/2018		M	4,018	<u>(5)</u>	04/08/2025	Common Stock	4,018

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Edgar Filing: PATRICK DEVAL L - Form 4

Director 10% Owner Officer Other

PATRICK DEVAL L
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CA 94080

X

Signatures

/s/Lesley Ann Calhoun, as
Attorney-in-Fact

07/10/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents the weighted average sale price of the shares sold ranging from \$43.35 to \$43.85 per share. The Reporting Person will
(1) provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 20,
(2) 2017, subject to the recipient's continued service on the Issuer's Board of Directors, such that this option became fully exercisable on June 20, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.

The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on
(3) September 11, 2015, such that this option became fully exercisable on August 11, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer.

The shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on August
(4) 23, 2015, such that this option is fully exercisable on July 23, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.

25% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option
(5) shall vest and become exercisable in 12 equal quarterly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.